The healthcare sector significantly contributes to global greenhouse gas emissions, with surgical pathology (SP) playing a notable role. This review explores the ecological transformation of SP, offering a global overview of existing challenges and sustainable initiatives worldwide. While some countries, such as the UK and France, have developed national strategies to reduce the carbon footprint of healthcare, including SP, many regions remain at an early stage of implementing green practices. Several studies have assessed the carbon footprint of SP, focusing on key aspects such as laboratory operations, pathology procedures and functional units, highlighting materials and transportation as major contributors to emissions. The integration of digital pathology and artificial intelligence (AI) presents opportunities to enhance efficiency and address medical deserts but also poses challenges due to the associated energy consumption. Local initiatives such as the ‘Transformation Ecologique en Anatomie et Cytologie Pathologiques’ (Ecological transformation in SP) or TEAP collective in France, Belgium’s ‘Green Team’ and sustainable practices in Tunisia and New Zealand demonstrate the global effort to reduce the environmental impact of SP. Key strategies discussed include ecodesign of care, circular economy practices, green AI and partnerships with industry. However, achieving meaningful reductions in SP’s environmental impact requires international cooperation and support from national health policies. This review emphasises the importance of collaborative efforts to implement sustainable solutions without compromising the quality and safety of healthcare services.
Aims: Primary cutaneous marginal zone lymphoma (PCMZL) is considered a lymphoproliferative disorder (International Consensus Classification, ICC) or an overt lymphoma (WHO‐HAEM5). Seeking evidence for a reactive process or true lymphoma, we retrieved recurrent PCMZLs from the French Study Group of Cutaneous Lymphoma (GFELC) database.Methods: Histology, phenotype (light‐chain restriction, immunoglobulin, and immune‐receptor translocation‐associated protein‐1 [IRTA1] expression) and B‐cell clonality at diagnosis and recurrence were compared according to recurrence site (local, locoregional, or distant) and outcomes.Results: Initial lesions of the 61 patients (mean age 52) were mostly isolated on the trunk (48%) and classified T1 (70%). Times to first recurrence for local, locoregional, and distant recurrences, were 20, 29, and 37 months, respectively. Light‐chain restriction type did not differ significantly between local/locoregional recurrences and distal recurrences (P = 0.06; n = 60). The same B‐cell clones were identified for 23/42 local/locoregional recurrences, while 5/19 distant recurrences showed different clonal profiles (P = 0.0003). No tumour expressed IRTA1. Fifty‐eight tumours were heavy‐chain (IgG/IgG4) class‐switched PCMZLs and 3 IgM+/IgD– PCMZLs. All IgM+ tumours underwent either transformation (skin or brain) into diffuse large B‐cell lymphomas (DLBCLs) and extracutaneous spreading.Conclusion: As suggested by WHO‐HAEM5, immunoglobulin phenotype assessment (IgM alongside IgD) appears to be a possible valuable tool in the initial diagnosis of PCMZL to differentiate between the indolent class‐switched PCMZL (IgM‐negative) and IgM+ (IgD–) PCMZL, which has an uncertain prognosis. The variation in B‐cell rearrangements and light chain restriction observed in distant recurrences of PCMZL may suggest different antigen‐driven stimulation processes.
Formalin is universally acknowledged as the gold standard for tissue fixation. However, it is a dangerous toxic chemical without any realistic substitute. Therefore, decreasing its use seems to be the only way to reduce its environmental impact. We assessed the feasibility of an innovative formalin recycling circuit based on the reuse of formalin following biopsy removal and paper filtration. We also assessed the efficiency of a policy of less formalin use in routine practice without compromising work quality and security. The recycled formalin was equivalent to new formalin in terms of its chemical and molecular properties, as well as the fixation, analysis, and storage of tissue samples. Moreover, its use for fixation did not affect molecular analyses. We calculate that our process would have decreased the total consumption of formalin in 2022 by 26% compared to 2021. This corresponds to financial savings of €4620, a 2434 kg CO2 equivalent reduction in greenhouse gases, and substantial decreases in toxicity to humans and freshwater. Our recycled formalin circuit is a simple, easy-to-implement, efficient way to mitigate the environmental impact of formalin in surgical pathology without compromising the quality of analysis and the safety of the pathology staff.
Diagnosing atypical melanocytic tumors can be challenging without molecular characterization, necessitating simple tools to enhance diagnostic accuracy in daily practice. This study retrospectively analyzed the utility of p16 immunohistochemistry (IHC) and 9p21 fluorescence in situ hybridization (FISH) on 206 tumors referred for expert second opinion. The performance of p16 and 9p21 was compared to histological diagnosis (both initial and final respectively without and with p16 and 9p21 status), histological subtype, and follow-up data. Negative p16 immunolabelling detected 90% of malignant cases, while only 11% of benign tumors were p16 negative. Homozygous 9p21deletion detected 42% of malignant tumors and excluded 95% of benign ones. Heterozygous deletion showed no diagnostic value. Homozygous 9p21 deletion significantly improved diagnostic confidence (P < 0.001), leading to tumor upgrading (n = 23) or melanoma confirmation (n = 22). Among 97 patients with follow-up, 17 had adverse outcomes. Kaplan–Meier analysis showed no significant difference in progression-free survival between groups (P = 0.64). Combining both techniques ultimately enhanced histological diagnostic confidence in daily practice. However, in cases where p16 is negative without homozygous deletion, or where histological malignancy is uncertain and p16 positive, other p16-inactivation mechanisms or molecular anomalies should be considered, necessitating further molecular investigations.